Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
NCT00438854Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2006
- Primary completion
- Oct 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in chronic lymphocytic leukemia (CLL), sponsored by Massachusetts General Hospital. Started Dec 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00438854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00438854.